Fedratinib and pacritinib may reduce the leukaemic burden of JAK2-alterated ALL with superior or equivalent efficacy to ruxolitinib, potential improving complete remission rates and associating with less treatment-associated adverse events. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.